Breast diseases

PubMed Free Full Text

Triple negative breast cancer

Africa

• BMJ Open
  • Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis [2022]

Australia

• Hereditary Cancer in Clinical Practice
  • Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia [2021]

Barbados

• Cancer
  • High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer [2020]

Brazil

• BMC Cancer
  • Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology [2022]

Canada

• Current Oncology
  • Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer [2024]

China

• Cancer Medicine
  • Cost-effectiveness analysis of tumor-infiltrating lymphocytes biomarkers guiding chemotherapy de-escalation in early triple-negative breast cancer [2023]

• Frontiers in Public Health
  • Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis [2024]

Developed countries

• PharmacoEconomics
  • Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review [2022]

Europe

• European Medicines Agency
  • The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer [2022]

Finland

• Breast Cancer Research and Treatment
  • FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population [2017]

Germany

• BMC Cancer
  • Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients [2013]

• Geburtshilfe und Frauenheilkunde
  • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice [2019]

India

• JCO Global Oncology
  • Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer [2020]

• South Asian Journal of Cancer
  • Practical consensus recommendations on management of triple-negative metastatic breast cancer [2018]

International

• Asian Journal of Surgery
  • Efficacy of breast conservative surgery versus modified radical mastectomy for triple-negative breast cancer: A systematic review and meta-analysis [2022]

• Breast
  • A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer [2022]

• Cancers
  • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer [2021]

• Cochrane Database of Systematic Reviews
  • Platinum-based chemotherapy for early triple-negative breast cancer [2023]

• Technology in Cancer Research & Treatment
  • Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review [2023]

Italy

• Cancer Treatment Reviews
  • Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review [2023]

• Cancers
  • Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) [2019]

Mexico

• Breast Cancer Research and Treatment
  • The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer [2015]

Republic of Korea

• PLoS ONE
  • Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population [2015]

Thailand

• PLoS ONE
  • Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer [2018]

United Kingdom

• National Institute for Health and Care Excellence
  • Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies [2022]
  • Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer [2022]
  • Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [2022]
  • Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer [2020]

United States

• Advances in Therapy
  • Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States [2023]

• American Society of Clinical Oncology
  • Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2022]
  • Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update [2022]

• Annals of Surgical Oncology
  • Identifying and Treating Those at Risk: Disparities in Rapid Relapse Among TNBC Patients in the National Cancer Database [2024]

• Breast Cancer Research and Treatment
  • Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing [2014]

• Frontiers in Public Health
  • Racial and regional disparities of triple negative breast cancer incidence rates in the United States: An analysis of 2011-2019 NPCR and SEER incidence data [2022]

• JAMA Network Open
  • Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US [2021]

• JNCCN
  • Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations [2022]

• Oncologist
  • Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities [2021]

West Africa

• JCO Global Oncology
  • Prevalence and Mortality of Triple-Negative Breast Cancer in West Africa: Biologic and Sociocultural Factors [2021]

{Related topics}

• Topic
  • Breast cancer